Grants Search Results

This grant funds an undergraduate student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Ewing Sarcoma (ES) is an aggressive pediatric cancer. The disease has the worst prognosis when metastases are present, however mechanisms promoting its spread are not clear. These researchers have discovered a new mode of ES spread – migration along nerves. The data indicates that this process is stimulated by a protein released from these nerves – neuropeptide Y (NPY). The student is helping to identify molecules present in ES that recognize NPY and promote their invasion along the nerves, as well as test strategies preventing this effect. If successful, this study may impact ES patients by preventing tumor dissemination.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Neuroblastoma is an often-deadly malignant childhood cancer. Research in the DeClerck lab has shown that non-cancerous stromal support cells in neuroblastoma tumors play an important role in the malignant behavior of the tumor by communicating between each other. A newly-recognized method for cell communication is via little vesicles called exosomes. These are released from one cell type and are captured by other cell types in the tumor and can affect tumor malignancy and resistance to therapy. In this project, the student is examining communication through such exosome vesicles between stromal cells and neuroblastoma tumor cells.

Unlike many other pediatric cancers, osteosarcoma has many abnormalities found on genetic analysis of the tumor itself. Dr. Sweet Cordero and colleagues hypothesize that some of these abnormalities could be used to predict what treatment might work best for each specific osteosarcoma patient. For example, many osteosarcomas have genetic alterations that block their ability to "repair" their DNA using specific pathways. One of these defective pathways is called the "homologous repair" pathway and another is called the "alternative lengthening of chromosomes" pathway. The inability of osteosarcoma tumors to repair their DNA using these pathways may make them susceptible to specific drugs. However, it is very likely that these drugs will need to be used in combination and not alone. A key need to advance osteosarcoma patient care is to define and use appropriate model systems to test drugs before using them in patients. This project is combining both preclinical studies in PDX models and a clinical trial to develop new ways to treat osteosarcoma patients with the goal being to improve survival for patients with relapsed and metastatic disease.

This multi-year grant is named for and funded by the Battle Osteosarcoma Hero Fund inspired by and established in honor of Charlotte, Dylan, Tyler and all OsteoWarriors. Led by parents, its mission is to raise funds for promising osteosarcoma precision oncology research to improve treatment options and outcomes for kids battling osteosarcoma.

Therapeutic access to pediatric solid tumors, especially in the context of metastatic disease, remains a tremendous challenge. Dr Daugaard and his team are developing new ways of targeting pediatric solid tumors by exploiting distinct changes to proteins expressed on the surface of tumor cells and in the tumor microenvironment. The St. Baldrick's Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci's values including creativity, collaboration, and commitment to early- to mid-career scientists.

Dr. Shlien is working to define the key molecular landmarks of aggressive childhood cancers. Understanding how these lethal tumors arise will lead to better treatment and surveillance. This will impact the management of these young patients, and improve the precision of cancer care. The St. Baldrick's Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci's values including creativity, collaboration, and commitment to early- to mid-career scientists.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. This year it is estimated that 800 children will be diagnosed with osteosarcoma (bone cancer). It is thought that sex hormones play a role in the onset of the disease, as more boys than girls get osteosarcoma and the cancer develops at the time of puberty. We hypothesize that a key molecule in estrogen signaling, that is crucial for normal bone, is turned off in osteosarcomas, preventing those cells from being normal bone. The student is helping to understand the molecular mechanisms of estrogen silencing in osteosarcomas.

This grant funds a medical school student to complete work in pediatric oncology research for the summer. The experience may encourage them to choose childhood cancer research as a specialty. Pilocytic astrocytoma is the most common brain tumor that occurs in children. Though it only rarely does so, when this tumor spreads, it becomes much more difficult to treat. This student is working to understand why these tumors spread.

Through this partnership with The Kids' Cancer Project, proceeds from St. Baldrick's events in Australia fund life-saving research in Australia.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a immunotherapy focused Clinical Research Associate to ensure that more kids can be treated on immunotherapy clinical trials, often their best hope for a cure.

Young adulthood is a time filled with exciting possibilities and also difficult challenges. People at this stage of life may be deciding on or attending school, selecting a career or working hard at their jobs, dating or in a relationship, and may be planning for or raising children. A cancer diagnosis does not fit into these plans and goals. Researchers are finding that the biology of the cancers in people of this age group are different, and increasing data indicates that adult patients with some cancers would benefit by being treated on what are traditionally pediatric therapies. Ochsner's Adolescent and Young Adult (AYA) Cancer and Survivor program is the first and only one of its kind in the region. The team is made up of professionals from pediatric and adult medicine. This program is designed for people between the ages of 15 and 39 years of age with cancer -newly diagnosed, actively in therapy and or cancer survivors. This grant supports a Nurse Coordinator who works with new patients in the combined AYA Cancer and Survivor Clinic, to ensure they have access to the best clinical trials for their cancer.

People between the ages of 15 to 40 years old with cancer have a lot of challenges like having to juggle their cancer diagnoses with their day to day lives - school, a job or family, and even things like going out with friends or keeping up with exercise or hobbies. They can feel isolated, afraid and unaware of new drugs that can help, or could be far away from hospitals that offers treatment through clinical trials. This grant supports an adolescent and young adult patient navigator to help young people address these issues throughout their treatment, get them the help they need and steer them towards newer treatments through trials that may increase their chance of a cure from cancer.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The Jim Brady's St. Baldrick's grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. This grant is named in honor of the 20th annual head-shaving event at Jim Brady's and to celebrate its many volunteers over the years who have supported the event at the birthplace of St. Baldrick's.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a nurse navigator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.